We are live on
!
Find out more
ROTUOC
Regents of the University of California Portfolio holdings
AUM
$4.36B
1-Year Est. Return
33.89%
This Fund
S&P 500
This Quarter
Est. Return
+7.15%
1 Year Est. Return
+33.89%
3 Year Est. Return
+86.09%
5 Year Est. Return
+63.96%
10 Year Est. Return
+870.04%
AUM
$538M
AUM Growth
+$10.8M
(+2%)
Cap. Flow
-$26.8M
Cap. Flow
% of AUM
-4.97%
Top 10 Holdings %
Top 10 Hldgs %
97.68%
Holding
34
New
–
Increased
–
Reduced
4
Closed
5
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blue Owl Capital
OBDC
|
+$21.9M |
| 2 |
Tenaya Therapeutics
TNYA
|
+$1.87M |
| 3 |
Erasca
ERAS
|
+$825K |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$692K |
| 5 |
Affirm
AFRM
|
+$482K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 93.35% |
| 2 | Healthcare | 2.27% |
| 3 | Consumer Staples | 1.74% |
| 4 | Energy | 0.68% |
| 5 | Materials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Blue Owl Capital
OBDC
$5.81B
| $319M | 59.37% |
25,336,768
-1,703,751
| -6% | -$21.9M |
|
2
Blue Owl Capital
OWL
$18.9B
| $177M | 32.98% |
16,017,491
| – | – |
|
3
Estee Lauder
EL
$31.6B
| $8.23M | 1.53% |
33,400
| – | – |
|
4
Intellia Therapeutics
NTLA
$1.68B
| $4.15M | 0.77% |
111,440
| – | – |
|
5
ExxonMobil
XOM
$652B
| $3.68M | 0.68% |
33,600
| – | – |
|
6
Air Products & Chemicals
APD
$68B
| $2.93M | 0.54% |
10,200
| – | – |
|
|
7
Tenaya Therapeutics
TNYA
$175M
| $2.74M | 0.51% |
960,957
-665,793
| -41% | -$1.87M |
|
8
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27.3B
| $2.57M | 0.48% |
5,600
| – | – |
|
9
Merck
MRK
$330B
| $2.3M | 0.43% |
21,600
| – | – |
|
10
S&P Global
SPGI
$123B
| $2.07M | 0.38% |
6,000
| – | – |
|
11
Berkshire Hathaway Class B
BRK.B
$1.09T
| $1.77M | 0.33% |
5,723
| – | – |
|
12
Texas Instruments
TXN
$255B
| $1.21M | 0.22% |
6,500
| – | – |
|
13
Pfizer
PFE
$151B
| $1.13M | 0.21% |
27,645
| – | – |
|
14
Coca-Cola
KO
$374B
| $1.12M | 0.21% |
18,000
| – | – |
|
|
MRSH
15
Marsh
MRSH
$91B
| $866K | 0.16% |
5,200
| – | – |
|
16
Honeywell
HON
$74.3B
| $807K | 0.15% |
4,481
| – | – |
|
|
17
Erasca
ERAS
$6.49B
| $711K | 0.13% |
236,236
-226,736
| -49% | -$825K |
|
18
Verizon
VZ
$196B
| $690K | 0.13% |
17,735
| – | – |
|
19
Wells Fargo
WFC
$268B
| $677K | 0.13% |
18,106
| – | – |
|
20
Walt Disney
DIS
$180B
| $601K | 0.11% |
6,000
| – | – |
|
21
Sana Biotechnology
SANA
$1.12B
| $511K | 0.09% |
156,254
| – | – |
|
22
Caribou Biosciences
CRBU
$170M
| $481K | 0.09% |
90,652
| – | – |
|
23
GE Aerospace
GE
$377B
| $479K | 0.09% |
6,276
-1,764
| -22% | -$118K |
|
24
AT&T
T
$167B
| $417K | 0.08% |
21,688
| – | – |
|
25
Automatic Data Processing
ADP
$108B
| $345K | 0.06% |
1,550
| – | – |
|
Similar funds
SFM
EC
EQF
NEI
FIS
CAU
IUHSA
CW
Regents of the University of California's Q1 2023 Portfolio in Review
As of Q1 2023, Regents of the University of California held 34 positions worth $538M, up 2% from $527M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Regents of the University of California withdrew a net $26.8M in Q1 2023, closing 5 positions and reducing 4 holdings. Its most notable exit was RAPT Therapeutics, an estimated $692K position sold in full.
By sector, the portfolio is most concentrated in Financials at 93% of assets, up from 93% a quarter earlier, followed by Healthcare and Consumer Staples.
- Regents of the University of California's biggest Q1 2023 reduction was Blue Owl Capital, cutting an estimated $21.9M.
- Regents of the University of California fully exited RAPT Therapeutics in Q1 2023, selling an estimated $692K.
- Regents of the University of California's ten largest holdings make up 98% of its $538M portfolio in Q1 2023.
- Regents of the University of California opened 0 new positions and closed 5 in Q1 2023.
- Regents of the University of California's portfolio value rose 2% quarter-over-quarter to $538M.
Based on Regents of the University of California's 13F filing for Q1 2023, filed 5 May 2023.